Evidence map›Paper›PMID 40963609›Full record

ArticleFrontiers in immunology2025

Upper respiratory tract immunization with Pam

Erica L Stewart, Skye Stockdale, Matt D Johansen, Lachlan Smith, Sibel Alca, Joshua W C Maxwell, Duc H Nguyen, Stefan Miemczyk, Guanshu Zhao, Stuart Turville and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Erica L StewartTuberculosis Research Program, Centenary Institute, The University of Sydney, Sydney, NSW, Australia.
Skye StockdaleSydney Institute for Infectious Diseases and the Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.
Matt D JohansenCentre for Inflammation, Centenary Institute and University of Technology Sydney, Faculty of Science, School of Life Sciences, Sydney, NSW, Australia.
Lachlan SmithSchool of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
Sibel AlcaSchool of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
Joshua W C MaxwellSchool of Chemistry, Faculty of Science, The University of Sydney, NSW, Australia.
Duc H NguyenCentre for Inflammation, Centenary Institute and University of Technology Sydney, Faculty of Science, School of Life Sciences, Sydney, NSW, Australia.
Stefan MiemczykCentre for Inflammation, Centenary Institute and University of Technology Sydney, Faculty of Science, School of Life Sciences, Sydney, NSW, Australia.
Guanshu ZhaoCentre for Inflammation, Centenary Institute and University of Technology Sydney, Faculty of Science, School of Life Sciences, Sydney, NSW, Australia.
Stuart TurvilleThe Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
James A TriccasSydney Institute for Infectious Diseases and the Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.
Megan SteainSydney Institute for Infectious Diseases and the Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.
Scott N ByrneSchool of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
Philip M HansbroCentre for Inflammation, Centenary Institute and University of Technology Sydney, Faculty of Science, School of Life Sciences, Sydney, NSW, Australia.
Richard J PayneSchool of Chemistry, Faculty of Science, The University of Sydney, NSW, Australia.
Warwick J Britton *Tuberculosis Research Program, Centenary Institute, The University of Sydney, Sydney, NSW, Australia.
Anneliese S Ashhurst *Sydney Institute for Infectious Diseases and the Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Injected COVID-19 vaccines protect against severe disease, but do not induce robust mucosal immune responses. Nasal vaccines offer the advantage of local immunity to block viral infection and transmission. Previously we showed immunization of a Pam

Indexed as

COVID-19COVID-19 VaccinesSARS-CoV-2Spike Glycoprotein, CoronavirusAdjuvants, ImmunologicAdministration, IntranasalAnimalsAntibodies, NeutralizingAntibodies, ViralFemaleHumansImmunizationMiceMice, Inbred BALB CNasal MucosaAdjuvants, ImmunologicAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2COVID-19mucosal adjuvantmucosal immunitymucosal vaccinenasal vaccinesSARS-CoV-2subunit vaccinationTLR2 agonist

Identifiers

PMID40963609
PMCPMC12436419

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.